Abstract
Dipeptidyl peptidase (DPP)-4 inhibitors are often used to treat type 2 diabetes patients due to their characteristics of safety and tolerance, with good diabetic control. Ileus has been reported to be a rare side effect of DPP-4 inhibitor therapy. However, until recently, the potential for ileus following treatment with DPP-4 inhibitors was only considered in patients with a past history of abdominal surgery and ileus. We herein present case of paralytic ileus that may have been caused by linagliptin. The patient was hospitalized for meningitis; he had a past history of cerebral hemorrhage, but no history of abdominal surgery or ileus. He subsequently developed paralytic ileus with vomiting and a stomachache. However, his condition recovered following conservative therapy with the discontinuation of linagliptin. This case may have been associated with diabetic gastroparesis, meningitis or the patient's past history of cerebral hemorrhage. The details of this case suggest that using DPP-4 inhibitors may induce ileus as a severe side effect in patients without a past history of abdominal surgery or ileus.
